Professor Dr Uli Brödl

Grünenthal has appointed Professor Dr Uli Brödl as CSO

Grünenthal has announced that Professor Dr Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board.

Uli has more than 15 years of industry experience. He joins Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim’s Venture Fund Investment Committee.

In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas. He worked at the interface of R&D, Commercial and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine.

Earlier in his career, Uli led Boehringer Ingelheim’s Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Canada Incubator, an innovation lab to develop innovative healthcare solutions.

Uli graduated as a Medical Doctor from Ludwig-Maximilians University Munich. He is a board-certified internist and endocrinologist and an Adjunct Professor of Internal Medicine at the Ludwig Maximilan University of Munich.

“The unique focus on improving the quality of life of underserved patients suffering from pain attracted me to Grünenthal,” says Uli. “I look forward to joining the team and further driving Grünenthal’s innovation pipeline.”

“With Uli, we have been able to attract an excellent leader,” says Gabriel Baertschi, CEO of Grünenthal. “His extensive experience in R&D and commercial functions combined with Uli’s drive to bring innovative medicines to patients will help us propel our vision of a world free of pain.”